Monoamine oxidases: to inhibit or not to inhibit.
Monoamine oxidase (MAO) inhibitors were developed as antidepressants but many drugs, including the novel oxazolidinone antibacterial agents, share similar molecular properties and have MAO inhibitory activity. Factors important for binding antidepressants and modifications to decrease binding of oxazolidinones to avoid undesirable vascular effects are discussed.
Ramsay
R R
RR
Centre for Biomolecular Sciences, University of St Andrews, North Haugh, St Andrews KY16 9ST, Scotland, UK. rrr@st-and.ac.uk
Gravestock
M B
MB
D000818:Animals; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology; D000928:Antidepressive Agents / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D001665:Binding Sites; D002227:Carbazoles / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D008995:Monoamine Oxidase / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D023303:Oxazolidinones / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology; D021281:Quantitative Structure-Activity Relationship; D013237:Stereoisomerism
D000890:Anti-Infective Agents; D000928:Antidepressive Agents; D002227:Carbazoles; D008996:Monoamine Oxidase Inhibitors; D023303:Oxazolidinones; C082644:tetrindole; D008995:Monoamine Oxidase; C009830:pirlindole